期刊文献+

丹参酮Ⅱ_A磺酸钠注射液的安全性评价 被引量:16

Safety of sodium tanshinone Ⅱ_A sulfonate injection
在线阅读 下载PDF
导出
摘要 目的丹参酮ⅡA磺酸钠临床用于抗肿瘤、治疗心脑血管疾病以及抗菌消炎等,文中评价丹参酮ⅡA磺酸钠注射液的安全性。方法以等渗氯化钠溶液为阴性对照进行体外溶血试验,兔耳缘静脉血管刺激试验,肌肉注射刺激试验和豚鼠全身过敏性试验。结果丹参酮ⅡA磺酸钠注射液(临床使用浓度1mg/m l)3 h内不引起溶血或红细胞凝集反应。丹参酮ⅡA磺酸钠注射液(4mg/kg)对兔耳缘静脉和股四头肌无刺激作用,不引起豚鼠全身过敏反应。结论丹参酮ⅡA磺酸钠注射液在本实验条件下安全性较好,可供临床注射使用。 Objective Sodium tanshinone ⅡA sulfonate(STS) is clinically used in the treatment of cancer,cardiovascular diseases and bacterial infections.The purpose of this study was to evaluate the safety of STS injection.Methods We conducted the hemolytic test in vitro,the stimulating test in the auricular veins and muscles of rabbits,and the allergic test in guinea pigs,with normal saline used as the control.Results STS injection at the concentration of 1 mg/ml induced no hemolysis or reaction in erythrocyte agglutination at 3 hours,nor stimulus to the auricular veins and muscles of the rabbits at 4 mg/kg,nor systemic anaphylaxis in the guinea pigs.Conclusion Under experimental conditions,STS injection is safe for clinical use.
出处 《医学研究生学报》 CAS 2010年第5期474-476,共3页 Journal of Medical Postgraduates
基金 国家自然科学基金(30472055)
关键词 丹参酮ⅡA磺酸钠注射液 溶血试验 过敏反应 Sodium tanshinone ⅡA sulfonate Hemolytic test Hypersensitivity
作者简介 曹晓梅(医学硕士) 通讯作者:陈小铭,E-mail:chenxiaoming63@hotmail.com
  • 相关文献

参考文献5

二级参考文献14

  • 1修春英,蔡辉.溶血磷脂酸与缺血性心脏病[J].医学研究生学报,2006,19(2):172-174. 被引量:3
  • 2Garrity JA,Bahn RS.Pathogenesis of Graves ophthalmopathy:Implications for prediction,prevention and treatment[J].Am J Ophthalmol,2006,142(1):147-153.
  • 3Matos K,Manso PG,Marback E,et al.Protein expression of VEGF,IGF-1 and FGF in retroocular connective tissues and clinical correlation in Graves' ophthalmopathy[J].Arq Bras Oftalmol,2008,71(4):486-492.
  • 4Prabhakar BS,Bahn RS,Smith TJ,et al.Current perspective on the pathogenesis of Graves' disease and ophthalmopathy[J].Endocr Rev,2003,24(6):802-835.
  • 5Prabhakar BS,Bahn RS,Smith TJ,et al.Current perspective on the pathogenesis of Graves'disease and ophthalmopathy[J].Endocr Rev,2003,24(6):802-805.
  • 6Martins JR,Furlanetto RP,Oliveira LM,et al.Comparison of practical methods for urinary glycosaminoglycans and serum hyaluronan with clinical activity scores in patients with Graves'ophthalmopathy[J].Clin Endocr,2004,60(10):726-733.
  • 7Brown RD,Ambler SK,Mitchell MD,et al.The cardiac fibroblast:therapeutic target in myocardial remodeling and failure[J].Annu Rev Pharmacol Toxicol,2005,45(6):657-687.
  • 8Sengupta S,Wang Z,Tipps R,et al.Biology of LPA in health and disease[J].Semin Cell Dev Biol,2004,15(5):503-512.
  • 9Karliner JS,Honbo N,Summers K,et al.The lysophospholipids sphingosine-1-phosphate and lysophosphatidic acid enhance survival during hypoxia in neonatal rat cardiac myocytes[J].J Mol Cell Cardiol,2001,33(9):1713-1717.
  • 10Lijnen PJ,Petrov VV,Fagard RH.Induction of cardiac fibrosis by transforming growth factor-beta(1)[J].Mol Genet Metab,2000,71(1-2):418-435.

共引文献338

同被引文献147

引证文献16

二级引证文献66

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部